SNAC2: This phase III trial is assessing the effect of sentinal node based management on risk of recurrence in patients with early stage breast cancerA randomised phase III study to determine in women with early breast cancer whether sentinel node based management increases the risk of loco-regional recurrence and in particular, axillary recurrence, compared with axillary clearance in any subgroup of women.

Summary

SNAC-2 is a national trial comparing two operations for detecting cancer cells in the lymph nodes of women with early breast cancer. The two operations are: 1) axillary clearance and 2) sentinel node biopsy. The standard of treatment for early stage breast cancer is axillary clearance which is the removal of most of the lymph nodes under the armpit (axilla). The new treatment is sentinel node biopsy where only the first few lymph nodes most closely related to the cancer are removed. We know that removing only the sentinel nodes may cause fewer side effects than doing an axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours.

Conditions

This trial is treating patients with breast cancer.

More information